Compile Data Set for Download or QSAR
Report error Found 417 Enz. Inhib. hit(s) with Target = 'Isoform 3 of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (hPDE4D3)' Sort by
LigandPNGBDBM285598(US10077269, Example 71 | 3-(3-chloro-4-methylpheny...)
Affinity DataIC50: 2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 2.35nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285634(US10077269, Example 104 | 3-(4-chloro-3,5-difluoro...)
Affinity DataIC50: 4.69nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285537(US10077269, Example 10 | 3-(4-chloro-3-fluoro-phen...)
Affinity DataIC50: 6.84nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577126(US11472805, Example 32 | 10-(4-Chloro-3-fluorophen...)
Affinity DataIC50: 9.07nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285572(US10077269, Example 45 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 11.7nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577123(US11472805, Example 29 | 10-(4-Chloro-5-fluoro-2-m...)
Affinity DataIC50: 12.7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285556(US10077269, Example 29 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 13.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285568(US10077269, Example 41 | N-cyclopropyl-3-(3-fluoro...)
Affinity DataIC50: 16.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577135(US11472805, Example 40 | 8-Cyclopropyl-10-(3,4,5-t...)
Affinity DataIC50: 17.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285540(US10077269, Example 13 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 17.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285576(US10077269, Example 49 | azetidin-1-yl[3-(3-chloro...)
Affinity DataIC50: 19nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577143(US11472805, Example 48 | 10-(3-Chlorophenyl)-8-cyc...)
Affinity DataIC50: 19.8nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285627(US10077269, Example 97 | 3-(4-chloro-5-fluoro-2-me...)
Affinity DataIC50: 20nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285563(US10077269, Example 36 | 3-(3-chlorophenyl)-N-cycl...)
Affinity DataIC50: 21nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577172(US11472805, Example 76 | 10-(4-Chloro-3-fluorophen...)
Affinity DataIC50: 21.6nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285603(US10077269, Example 76 | azetidin-1-yl{3-[2-(diflu...)
Affinity DataIC50: 22.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577128(US11472805, Example 34 | 2-Chloro-5-(8-cyclopropyl...)
Affinity DataIC50: 23.3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285574(US10077269, Example 47 | azetidin-1-yl[3-(4-chloro...)
Affinity DataIC50: 23.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285557(US10077269, Example 30 | 3-(4-chlorophenyl)-N-(2-m...)
Affinity DataIC50: 24.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285602(US10077269, Example 75 | N-cyclopropyl-3-[2-(diflu...)
Affinity DataIC50: 24.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285616(US10077269, Example 86 | azetidin-1-yl[3-(2,2-difl...)
Affinity DataIC50: 25nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285595(US10077269, Example 68 | 3-(4-chloro-2-fluoropheny...)
Affinity DataIC50: 25.1nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285620(US10077269, Example 90 | 3-(4-cyano-3-fluorophenyl...)
Affinity DataIC50: 25.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285611(US10077269, Example 81 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 25.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285529(US10077269, Example 2 | 3-(4-Chlorophenyl)-N-cyclo...)
Affinity DataIC50: 27.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577130(US11472805, Example 36 | 10-(3-Chloro-4-fluorophen...)
Affinity DataIC50: 28.1nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM577094(US11472805, Example 11 | (7S)-10-(4-Chlorophenyl)-...)
Affinity DataIC50: 28.7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM577182(US11472805, Example 86 | 10-Cyclopentyl-8-cyclopro...)
Affinity DataIC50: 29nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285626(US10077269, Example 96 | 3-(4-chloro-2,5-difluoro-...)
Affinity DataIC50: 29.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577174(US11472805, Example 78 | 8-Acetyl-10-(4-chlorophen...)
Affinity DataIC50: 30.6nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285534(US10077269, Example 7 | 3-(4-Chloro-3-fluorophenyl...)
Affinity DataIC50: 34.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577079(US11472805, Example 4 | 4-(8-Cyclopropyl-9-oxo-6,7...)
Affinity DataIC50: 36.3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285562(US10077269, Example 35 | 3-(3-chloro-5-fluoropheny...)
Affinity DataIC50: 37nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577152(US11472805, Example 57 | 10-(4-Chlorophenyl)-8-(5-...)
Affinity DataIC50: 38.3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285573(US10077269, Example 46 | 3-(4-chlorophenyl)-N-[(1R...)
Affinity DataIC50: 39.3nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285613(US10077269, Example 83 | azetidin-1-yl[3-(3,4-dich...)
Affinity DataIC50: 40nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285536(US10077269, Example 9 | 3-(4-Chloro-2,5-difluoroph...)
Affinity DataIC50: 40.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285622(US10077269, Example 92 | 3-(4-cyano-2,5-difluoroph...)
Affinity DataIC50: 42.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577176(US11472805, Example 80 | 10-(4-Chlorophenyl)-N-eth...)
Affinity DataIC50: 42.8nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285612(US10077269, Example 82 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 43.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285614(US10077269, Example 84 | azetidin-1-yl[3-(3-chloro...)
Affinity DataIC50: 44.4nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577101(US11472805, Example 16 | 4-(8-Cyclopropyl-9-oxo-3,...)
Affinity DataIC50: 45.5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285550(US10077269, Example 23 | 4-[2-(azetidin-1-ylcarbon...)
Affinity DataIC50: 45.8nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285561(US10077269, Example 34 | 3-(3-chloro-5-fluoropheny...)
Affinity DataIC50: 47nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285615(US10077269, Example 85 | 3-(4-chlorophenyl)-N-ethy...)
Affinity DataIC50: 47.2nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285555(US10077269, Example 28 | 3-(3,5-dichlorophenyl)-N-...)
Affinity DataIC50: 49nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM285530(US10077269, Example 3 | Azetidin-1-yl[3-(3,5-diflu...)
Affinity DataIC50: 51.9nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

LigandPNGBDBM577173(US11472805, Example 77 | 10-(4-Chloro-2,5-difluoro...)
Affinity DataIC50: 56.2nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

LigandPNGBDBM285612(US10077269, Example 82 | 3-(4-chloro-3-fluoropheny...)
Affinity DataIC50: 56.5nMAssay Description:The PDE4A3, PDE4B1, PDE4C1 and PDE4D3 assays use the Scintillation Proximity Assay (SPA) technology to measure the inhibition of human recombinant PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 417 total ) | Next | Last >>
Jump to: